Profile
Dr. Yu-Pei Chen is currently an attending physician of Radiation Oncology in Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, China. Dr Chen’s research mainly focused on individualized treatment for nasopharyngeal carcinoma and the underlying molecular biology. He is appointed as one of the members for the Naso-pharyngeal Cancer Clinical Trials Planning Meeting of the U.S. National Cancer Institute, and also serves as one member of the Chinese Society of Clinical Oncology (CSCO) NPC Expert Committee. He has published more than 30 peer-reviewed papers, including some papers in renowned journals such as NEJM, Lancet, BMJ, JAMA Oncol, Cell Res, Ann Oncol, J Pineal Res, J Hematol Oncol, Nature Commun, Clin Cancer Res, J ImmunoTher Cancer, etc.
Interests
The research focus of Dr. Yu-Pei Chen centers on the comprehensive treatment and precision medicine of nasopharyngeal carcinoma (NPC). Design and conduct of phase II and III clinical trials in the field of NPC. Preclinical basic researches focusing on biomarkers, prognostic molecules, and signal pathways related with the development of NPC.
Education
09/2015-06/2017 M.D., Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, China
09/2009-09/2015 Bachelor, Sun Yat-sen University, Guangzhou, China
Publications
1. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Chen YP, Liu X, Zhou Q, Yang KY, Jin F, Zhu XD, Shi M, Hu GQ, Hu WH, Sun Y, Wu HF, Wu H, Lin Q, Wang H, Tian Y, Zhang N, Wang XC, Shen LF, Liu ZZ, Huang J, Luo XL, Li L, Zang J, Mei Q, Zheng BM, Yue D, Xu J, Wu SG, Shi YX, Mao YP, Chen L, Li WF, Zhou GQ, Sun R, Guo R, Zhang Y, Xu C, Lv JW, Guo Y, Feng HX, Tang LL, Xie FY, Sun Y, Ma J. Lancet. 2021
2. Nasopharyngeal carcinoma. Chen YP, Chan AT, Le QT, Blanchard P, Sun Y, Ma J. Lancet 2019
3. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. Chen YP, Ismaila N, Chua MLK, Colevas AD, Haddad R, Huang SH, Wee JTS, Whitley AC, Yi JL, Yom SS, Chan ATC, Hu CS, Lang JY, Le QT, Lee AWM, Lee N, Lin JC, Ma B, Morgan TJ, Shah J, Sun Y, Ma J. J Clin Oncol 2021
4. Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. Chen YP, Yin JH, Li WF, Li HJ, Chen DP, Zhang CJ, Lv JW, Wang YQ, Li XM, Li JY, Zhang PP, Li YQ, He QM, Yang XJ, Lei Y, Tang LL, Zhou GQ, Mao YP, Wei C, Xiong KX, Zhang HB, Zhu SD, Hou Y, Sun Y, Dean M, Amit I, Wu K, Kuang DM, Li GB, Liu N, Ma J. Cell Res 2020
5. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy. Chen YP, Wang YQ, Lv JW, Li YQ, Chua MLK, Le QT, Lee N, Colevas AD, Seiwert T, Hayes DN, Riaz N, Vermorken JB, O'Sullivan B, He QM, Yang XJ, Tang LL, Mao YP, Sun Y, Liu N, Ma J. Ann Oncol, 2019
6. A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Chen YP, Wang ZX, Chen L, Liu X, Tang LL, Mao YP, Li WF, Lin AH, Sun Y, Ma J. Ann Oncol, 2015
7. Comparative safety of immune checkpoint inhibitors in cancer: a systematic review and network meta-analysis. Xu C,# Chen YP,# Du XJ,# Liu JQ,# Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, Liu Q, Lin AH, Tang LL, Sun Y, Ma J. BMJ 2018
8. Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. Chen YP, Tang LL, Yang Q, Poh SS, Hui EP, Chan ATC, Ong WS, Tan T, Wee J, Li WF, Chen L, Ma BBY, Tong M, Tan SH, Cheah SL, Fong KW, Sommat K, Soong YL, Guo Y, Lin AH, Sun Y, Hong MH, Cao SM, Chen MY, Ma J. Clin Cancer Res 2018
9. Identification of Cross-Talk Between M 6 A and 5mC Regulators Associated With Onco-Immunogenic Features and Prognosis Across 33 Cancer Types. Chen YT, Shen JY, Chen DP, Wu CF, Guo R, Zhang PP, Lv JW, Li WF, Wang ZX, Chen YP. J Hematol Oncol 2020
10. Liquid Biopsy Tracking during Sequential Chemo-radiotherapy Identifies Distinct Prognostic Phenotypes in Nasopharynx Cancer. Lv J,# Chen Y,# Zhou G,# Qi Z,# Tan KRL, Wang H, Lin L, Chen F, Zhang L, Huang X, Liu R, Xu S, Chen Y, Ma J, Chua MLK, Sun Y. Nat Commun 2019
Update June 2022 by International Office, Sun Yat-sen University Cancer Center
